← Evidence map

ArticleCureus2024

Estimating the Economic Impact of Levalbuterol's Potential Transition From the National Reimbursement Drug List for the Treatment of Pediatric Asthma in China: A Budget Impact Analysis.

Tingke Tang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Estimating the Economic Impact of Levalbuterol's Potential Transition From the National Reimbursement Drug List for the Treatment of Pediatric Asthma in China: A Budget Impact Analysis. | OpenQuestion